Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269090 | 0.98 | HTR6 (0.35) | HTR6CNR1CHRNB2CHRNA4KCNH2 | |
| SCHEMBL31269124 | 0.90 | CNR1 (0.33) | CNR1CHRNB2CHRNA4KCNH2PIK3CD | |
| SCHEMBL31268787 | 0.89 | KCNH2 (0.33) | CNR1KCNH2PIK3CDSCN5ASCN9A | |
| SCHEMBL31269153 | 0.88 | CNR1 (0.33) | CNR1KCNH2PIK3CDSCN5ASCN9A | |
| SCHEMBL31269156 | 0.88 | NTRK1 (0.33) | CNR1KCNH2PIK3CDSCN5ASCN9A | |
| SCHEMBL31268791 | 0.87 | CNR1 (0.39) | CNR1KCNH2PIK3CDSCN5ASCN9A | |
| SCHEMBL31268880 | 0.87 | PIK3CD (0.32) | KCNH2PIK3CDSCN5ASCN9A | |
| SCHEMBL31321975 | 0.86 | HTR6 (0.42) | HTR6CNR1PIK3CD | |
| SCHEMBL31269289 | 0.86 | PIK3CD (0.34) | CNR1SUV39H2KCNH2PIK3CDSCN5A | |
| SCHEMBL31268997 | 0.85 | PIK3CD (0.35) | CNR1KCNH2PIK3CDSCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |